Current Event 2022

WEEK OF OCTOBER 31, 2022

The Future of Precision and Predictive Health Care

Japan Healthcare Week, featuring Conference Events in Tokyo (Oct. 31) and Awajishima (Nov. 2)

Upcoming Event on November 2nd, 2022

— The Future of Precision and Predictive Healthcare —

Japan Week 2022 | Meet American and Japanese Companies

WHEN

Awajishima Healthcare Forum

Nov 2nd, 2022
10:00 AM–5:00 PM (JT)

Followed by Networking Reception

WHERE

Awajishima Healthcare Forum:

Awaji Yumebutai International Conference Center Link

KEYNOTE
Andrew Cleeland

Chief Executive Officer,
Fogarty Innovation

Andrew Cleeland is the CEO of Fogarty Innovationseasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from earlystage startups to large multinationals.

Bio

— HEALTHCARE SYMPOSIUM AGENDA —
Awajishima, November 2nd, 2022

9:00 A.M. – 10:00 A.M.

REGISTRATION

10:00 A.M. – 10:30 A.M.

WELCOME AND OVERVIEW OF THE FORUM

10:30 A.M. – 11:15 A.M.

KEYNOTE SPEECH: INNOVATION FOR THE FUTURE OF PREDICTIVE HEALTHCARE

Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.

Bio

11:15 A.M. – 12:10 P.M.

SESSION 1: PREDICTIVE HEALTHCARE PROGRAMS AND SUPPORT FROM US & JAPAN – INCUBATORS/ACCELERATORS AND AN INTERNATIONAL ECOSYSTEM

After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.

Andrew Cleeland is the CEO of Fogarty Innovation. A seasoned executive with more than 30 years of experience in the medical device industry, he has held key leadership positions in organizations ranging from early–stage start–ups to large multinationals.

Bio

He received the B.S. degree, the M.S. degree in information and communication engineering, and the Ph.D. degree in electronic engineering, all from the University of Tokyo, in 1998, 2000, and 2003, respectively. From Apr. 2003 to Jun. 2006, he was an assistant professor at Department of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Osaka University. He became a lecturer at Department of Orthodontics and Dentofacial Orthopedics, Osaka University Dental Hospital in Jul. 2006.

Bio

[Current position]
Specially Appointed Professor, Co-Creation Organization, Osaka University
Invited Professor, Cybermedia Center, Osaka University
Visiting Professor, Tokushima University Research Support and Industry-Academia-Government Collaboration Promotion Department
Director, NPO Information Chemistry and Biology Society (CBI Society CBI Research Organization Next Generation Modality Research Institute)

Bio

12:10 P.M. – 12:30 P.M.

LUNCH BREAK

12:30 P.M. – 1:00 P.M.

LUNCH BREAK PRESENTATIONS

1:00 P.M. – 1:40 P.M.

KEYNOTE: THE FUTURE OF HEALTHCARE

1:40 P.M. – 2:35 P.M.

SESSION 2: PREDICTIVE & PROACTIVE HEALTHCARE NEEDS – DEVICES, DRUGS, BIOTECH, SUPPORT HARDWARE AND SOFTWARE – DIAGNOSTICS, THERAPIES, ROBOTICS, BIOMARKERS

Ryan was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and as an independent biotech consultant focused on adding value to early stage therapeutic and technology efforts. Early in his career Ryan worked in teams that applied cutting edge genetic engineering technologies to advance the development of gene therapy and cellular therapeutics.

Bio

David Case is a highly experienced intellectual property and venture capital transactions attorney admitted in the States of California, New York, Washington and Oregon. Prior to starting his own firm near Silicon Valley, David spent 20+ years as an associate and later equity partner at two different 1st tier international law firms practicing in New York City, Tokyo and Silicon Valley. David’s practice has a particular emphasis on life sciences and medical devices.

Bio

Dr. Burnett is a veteran in the medical device industry having founded many successful companies at various stages. During his undergraduate career at the University of Pennsylvania, he focused on bioengineering and spent a year at the Food and Drug Administration both testing devices and writing congressional reports on the current state-of-the-art devices.

Bio

2:35 P.M. – 2:45 P.M.

BREAK

2:45 P.M. – 3:35 P.M.

SESSION 3: DIGITAL HEALTH, ARTIFICIAL INTELLIGENCE, AND DIGITAL TWINS IN PREDICTIVE HEALTHCARE

Mika is a commercialization executive with extensive leadership experience in conceiving, planning, and launching disruptive medical technologies in 50 markets across North America, EMEA, Asia-Pacific, and Latin America. She has an exceptional track record of leading businesses from inception to across different clinical segments, including cardiovascular, fertility, and oncology.

Bio

Partha Ray is a mission-driven medtech innovation leader with over 25 years of deal & operating experience at leading global organizations. Partha has launched products and closed deals which benefit over 9M patients and generate over $20B/yr in revenues today.

Bio

In April of 2021, Iori Sumida moved to Accuray, Japan from Osaka University. Based on the clinical experience in medical physics he gained over 18 years, he currently works as the Senior Director to bring growth to the company from the marketing, physics, and clinical support aspects. His major skill is to develop artificial intelligence in radiation therapy and has been proved in the textbook published from the IOP.

Bio

Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.

Bio

Rob creates new businesses that address the unmet needs of patients, doctors, innovators and authorities. He is passionate about developing creative solutions for access to Japan’s healthcare market.

Bio

3:25 P.M. – 3:40 P.M.

BREAK

3:40 P.M. – 4:35 P.M.

SESSION 4: PREDICTIVE HEALTHCARE TARGETS – MENTAL HEALTH, COGNITIVE DISEASES, HOSPICE, CANCER, CARDIAC DISEASES, METABOLIC DISEASES, ICU, DAILYSIS, STROKE

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings. 

Bio

Martin Williams is a seasoned therapeutics developer with experience in multiple disease areas from start-up to large cap organizations. Previously, he held roles leading global product management for neurovascular devices and designing neurological diagnostics devices as an engineer. He was on the founding team and is currently leading business development efforts at Cognito Therapeutics, a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases entering Phase 3 studies with its novel approach to Alzheimer’s disease. 

Bio

He is a seasoned data scientist and previously served as the Chief Data Officer at a Japanese fin-tech startup, AnyPay and an AI OCR solution provider, AI inside. He and his co-founders founded ALY Inc. to accelerate DX and data usage in the healthcare/medical domain. He received his B.S. from UC Berkeley and M.S. in Data Science from GalvanizeU San Francisco.

Bio

4:35 P.M. – 5:45 P.M.

PRIVATE COMPANY PRESENTATIONS

Martin Williams is a seasoned therapeutics developer with experience in multiple disease areas from start-up to large cap organizations. Previously, he held roles leading global product management for neurovascular devices and designing neurological diagnostics devices as an engineer. He was on the founding team and is currently leading business development efforts at Cognito Therapeutics, a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases entering Phase 3 studies with its novel approach to Alzheimer’s disease. 

Bio

Founder and CEO of EchoPixel, a startup company pioneering medical imaging VR/AR solutions that are defining a new visualization paradigm Holographic Therapy Guidance (HTG), which allows doctors to perform minimally invasive surgeries using a digital twin of the patient that they experience as a hologram.

Bio

5:45 P.M. – 5:55 P.M.

CLOSING REMARKS

6:00 P.M. – 7:00 P.M.

SOCIAL NETWORKING